ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Larry Altstiel M.D. Ph.D., as Chief Medical Officer.   Brings decades of experience in Alzheimer’s research […]

Continue Reading

NemaLife and UC Davis enter into a research partnership to test the therapeutic potential of several novel psychoplastogens developed in David E. Olson’s Lab

NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.   NemaLife will evaluate the efficacy of these compounds using its high-throughput C. elegans-based in vivo screening platform. This high-throughput […]

Continue Reading

ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders

ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce it has mailed the Notice of Notice-and-Access (the “N&A Notice”) to shareholders of record of the Corporation as of April 01, 2022, in connection with the Annual General and Special Meeting of the Shareholders (the “Meeting”) of the Corporation to be […]

Continue Reading

ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has presented at the  American Academy of  Neurology (AAN) Annual Meeting held at the Washington State Convention Center in […]

Continue Reading

ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March […]

Continue Reading

How Significant Is Innovation in Nursing

The purpose of innovation in nursing is to improve the quality of care delivered and to reduce the associated risks.   The definition of innovation must be broad enough to include not only innovations that are brought about by changes in technology, but also change made through social, cultural, or behavioral factors. Innovation may also […]

Continue Reading
Close-up of man using nasal spray

Azelastine – the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of SARS-CoV-2

CEBINA GmbH, Central European Biotech Incubator and Accelerator with its partner URSAPHARM Arzneimittel GmbH, today announce new results demonstrating that azelastine, the active drug in Pollival®, URSAPHARM’s widely available anti-allergy nasal spray, is an effective anti-viral against the globally dominant omicron SARS-CoV-2 variant in laboratory conditions.   Previously, CEBINA and URSAPHARM have demonstrated that azelastine […]

Continue Reading
Top view of vitamin supplements on a black surface

bonebalance™ food supplement helps restore strong, flexible bones

bonebalance™ is a 100% natural food supplement approved for the dietary management of osteoporosis and osteopenia comprising high-quality specific Bioactive Collagen Peptides® that are clinically proven to help form bone matrix – the tissue that gives bones tensile strength and flexibility.   Easy to take bonebalance is presented as a flavourless powder that you simply […]

Continue Reading
Amanita mushroom

New global coalition launches initiative to secure a rescheduling of psilocybin under the 1971 UN Convention on Psychotropic Substances

Today marks the launch of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI), a global coalition working to promote and secure a rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances. Psilocybin is the active constituent in what are commonly known as ‘magic mushrooms’, a naturally occurring chemical compound that is increasingly seen as highly […]

Continue Reading